Figure 6

BC-PDE responses to FET + Trastuzumab. 40 BC-PDEs were treated with FET + Trastuzumab. (A) Fold change in drug-induced tumour apoptosis/necrosis compared to FET-induced tumour apoptosis/necrosis was determined for each patient sample. BC-PDEs were classified into High (H), Medium (M), and Low (L) drug-induced apoptosis/necrosis where H =  > 5, M =  > 2.5 and L =  < 2.5 fold change combined apoptosis and necrosis . (B) Fold change in drug-induced apoptosis (left) or combined apoptosis/necrosis (right) of FET + trastuzumab-treated samples compared to FET alone related to HER2 status. The Jonckheere-Terpstra trend test was performed showing trends for higher HER2 score and higher cell death response. (C) Fold change in drug-induced apoptosis (left) or combined apoptosis/necrosis (right) of FET + trastuzumab-treated samples compared to FET only related to molecular subtype. Statistics were performed using the Mann–Whitney test where p < 0.05 are shown. Values displayed above each group represent the number of patient samples in each group. * above the stacked bar graph indicates HER2-Enriched molecular subtype.